Results 41 to 50 of about 9,359 (237)
, 2021 Backgrounds: Insulin detemir(nn304) is a long-acting insulin analogue reported to provide more predictable blood glucose level throughout the day, leading to a lower within-subject variability compared to NPH insulin.
C. Kwok, L. Ho
semanticscholar +1 more source
Prevalence of pharamcologically-treated diabetes in term pregnancies in Haryana, India
Indian Journal of Endocrinology and Metabolism, 2017 Gestational diabetes mellitus (GDM) is common in pregnancy. Epidemiological studies have described the prevalence of GDM in the antenatal period, but do not assess the number of women who require pharmacological therapy at term.
Bharti Kalra +3 more
doaj +1 more source
Journal BiomedThe study of β-amyloid peptide (Aβ) interactions with protein and peptide ligands is a relevant research task. Aβ complexes with drugs that are considered as promising candidates for the therapy of Alzheimer’s disease are of particular interest.
M. Shevelyova +5 more
semanticscholar +1 more source
Managing feline diabetes: current perspectives [PDF]
, 2018 Diabetes mellitus is a common endocrine disease in cats. While type 2 diabetes is the most common form seen in cats, other underlying causes may contribute to insulin resistance.
Gottlieb, Susan, Rand, Jacquie
core +1 more source
Modern basal insulin analogs: An incomplete story
Indian Journal of Endocrinology and Metabolism, 2014 The currently available basal insulin does not completely mimic the endogenous insulin secretion. This has continued to promote the search for ideal basal insulin.
Awadhesh Kumar Singh +1 more
doaj +1 more source
Diabetes Care, 2020 OBJECTIVE To assess whether initiation of insulin glargine (glargine), compared with initiation of NPH or insulin detemir (detemir), was associated with an increased risk of breast cancer in women with diabetes.
M. Bradley +10 more
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský +14 more
wiley +1 more source
Flying under the radar: treatment of refractory hyperglycemia
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Clinicians are often presented with the scenario of what to do when one medication in a drug class has failed a therapeutic trial on a patient. We encountered a patient who developed profound resistance to glargine, aspart and regular insulin, but had a ...
S M Kandel, J A Cosgriff
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj +6 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2010 Jean-Pierre Le FlochDepartment of Diabetology, Medical Clinic, Villecresnes, FranceAbstract: Insulin detemir is an analog of human insulin designed to provide a long duration of basal insulin action.
Jean-Pierre Le Floch
doaj +2 more sources